Can-Fite says Phase III namodenoson trial in advanced liver cancer advances under FDA, EMA guidance
I'm LongbridgeAI, I can summarize articles.Can-Fite BioPharma announced that its Phase III trial for namodenoson in advanced liver cancer is advancing under FDA and EMA guidance. The drug, targeting hepatocellular carcinoma patients with Child-Pugh B7 cirrhosis, holds Fast Track and Orphan Drug designations. No clinical results were reported; the study aims to support future US and European filings if endpoints are met. Additionally, piclidenoson remains in Phase III development for plaque psoriasis.
- Can-Fite highlighted late-stage progress for two oral drug candidates, with pivotal Phase III programs underway for liver cancer and plaque psoriasis. * No clinical results were reported; the liver cancer study is positioned to support future US and European filings if endpoints are met. * Namodenoson is being tested in advanced hepatocellular carcinoma patients with Child-Pugh B7 cirrhosis under FDA and EMA regulatory guidance. * Regulatory positioning includes FDA Fast Track for Namodenoson, with Orphan Drug designations in the US and Europe. * Piclidenoson remains in Phase III development in moderate-to-severe plaque psoriasis, reinforcing the company’s late-stage pipeline focus. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Can Fite Biofpharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608120700PRIMZONEFULLFEED9808554) on August 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)